Fisher William A, Gilca Vladimir, Murti Michelle, Orth Alison, Garfield Hartley, Roumeliotis Paul, Rampakakis Emmanouil, Brown Vivien, Yaremko John, Van Buynder Paul, Boikos Constantina, Mansi James A
Department of Obstetrics and Gynaecology, Western University, London, ON N6A 3K7, Canada.
Département de Médecine Sociale Et Préventive, Faculté de Médecine, Institut Nationale de Sante Publique du Québec, Université Laval, Québec City, QC G1V 5B3, Canada.
Vaccines (Basel). 2022 Oct 21;10(10):1769. doi: 10.3390/vaccines10101769.
The adjuvanted trivalent influenza vaccine (aTIV) provides enhanced protection against influenza for infants but is not publicly funded (NPF). The objective of this prospective cohort study of parents with children 6 through 23 months of age was to understand how NPF status influences parental perceptions of approved but unfunded vaccines and their intentions to vaccinate. At healthy baby visits, clinicians provided parents with information about influenza and vaccination. Before and after these interactions, a research nurse assessed parents' intentions to vaccinate their children and their beliefs about the safety, efficacy, and necessity of vaccinating their children with aTIV in both publicly funded (PF) and NPF settings. Overall, 15 community practice clinics (n = 15 physicians) and nine public health clinics (n = 9 nurses) recruited 207 parents. The percentage of parents intending to immunize their children with aTIV decreased from 72% (vaccine PF, free of charge), to 42% (NPF, $25 per dose), to 27% (NPF, $50 per dose). Funding status strongly influenced whether parents perceived immunization with aTIV to be necessary, safe, and effective. Information on influenza and influenza vaccines should be provided to parents routinely to allow for well-informed decisions on the suitability of specific influenza vaccines for their child.
佐剂三价流感疫苗（aTIV）可为婴儿提供增强的流感防护，但未纳入公共资金资助（NPF）。这项针对6至23个月大儿童家长的前瞻性队列研究的目的是了解非公共资金资助状况如何影响家长对已获批但未获资助疫苗的看法及其接种意愿。在健康婴儿访视时，临床医生向家长提供有关流感和疫苗接种的信息。在这些互动前后，一名研究护士评估了家长在公共资金资助（PF）和非公共资金资助两种情况下为孩子接种aTIV的意愿以及他们对该疫苗安全性、有效性和必要性的看法。总体而言，15家社区诊所（15名医生）和9家公共卫生诊所（9名护士）招募了207名家长。打算用aTIV为孩子免疫的家长比例从72%（疫苗由公共资金资助，免费）降至42%（非公共资金资助，每剂25美元），再降至27%（非公共资金资助，每剂50美元）。资金状况强烈影响家长是否认为接种aTIV有必要、安全和有效。应定期向家长提供有关流感和流感疫苗的信息，以便他们就特定流感疫苗对其孩子的适用性做出明智的决定。
